Johnson & Johnson Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse
Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting its safety and efficacy in preventing relapse in schizophrenia. Caplyta (42 mg) is a once-daily oral atypical antipsychotic currently approved [...]